<DOC>
	<DOCNO>NCT00490412</DOCNO>
	<brief_summary>The purpose study test effect Vitamin D renal phosphate bone loss , common HIV infect adolescent young adult treat tenofovir .</brief_summary>
	<brief_title>Vitamin D Reabsorption Adolescents Young Adults With HIV Infection</brief_title>
	<detailed_description>ATN 063 test hypothesis population adolescent young adult HIV infection treat tenofovir part antiretroviral ( ARV ) combination regimen , vitamin D supplementation decrease renal phosphate loss , increase plasma phosphate , decrease plasma PTH , improve marker bone turnover , include decrease plasma N-telopeptide BAP .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 18 year 0 day 24 year 364 day HIV1 infection document licensed ELISA test kit confirm Western blot , HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA time prior study entry Currently treat stable FDAapproved ARV combination therapy , contain &gt; 3 antiretrovirals , &gt; 28 day , accord HRSA guideline . Treatment regimen start changed purpose participation study . Subjects receive therapy direction treat physician Willingness remain ARV combination therapy 12week duration study Ability willingness participate study provide write informed consent Willingness randomize receive either vitamin D placebo Prior hypersensitivity vitamin D History arteriosclerosis , renal stone , glomerulonephritis , nephrotic syndrome , hypercalcemia Lactation current pregnancy Active therapy malignancy Known presence gastrointestinal disease would interfere drug administration absorption Serological evidence Hepatitis B surface antigen ( HBsAg ) Confirmed creatinine clearance &lt; 90 ml/min ( calculate GFR serum creatinine use MDRD formula ) Grade 3 high clinical toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>